Telomir Pharms Stock Price, News & Analysis

Telomir Pharmaceuticals (NASDAQ:TELO) announced its participation in BIO 2025 in Boston as it prepares for IND submission of Telomir-1, a novel small molecule designed to elongate telomeres and reverse biological aging. The company plans to begin human dosing in H1 2026 and is advancing a rare-disease strategy focusing on conditions like Werner's syndrome, Wilson's disease, Progeria, and Dysphonia. Telomir-1 has shown promising preclinical results across multiple therapeutic areas, including vision restoration, longevity, metabolic disease, and oncology. In prostate cancer models, Telomir-1 reduced tumor growth by 50% while protecting healthy cells. The company is also developing Telomir-Ag2 for multidrug-resistant bacteria. Management will explore strategic collaborations, licensing opportunities, and potential M&A transactions during the conference.

Telomir Pharmaceuticals (NASDAQ:TELO) announced breakthrough preclinical results for Telomir-1, their oral therapeutic for age-related macular degeneration (AMD). In a 14-day study using a genetically modified zebrafish model, Telomir-1 demonstrated remarkable vision restoration and retinal regeneration capabilities. The study showed significant improvements in multiple FDA-recognized surrogate endpoints. Key results include: restoration of vision and coordinated swimming behavior, complete recovery of inner nuclear layer thickness, improved ganglion cell layer integrity, 50% reduction in reactive oxygen species levels, and zero mortality in treatment groups. The zebrafish model exhibited 15% retinal degeneration pre-treatment, affecting critical retinal layers. This breakthrough represents a potential paradigm shift in AMD treatment, as no oral drug has previously demonstrated such comprehensive retinal restoration and vision recovery in AMD models.

Telomir Pharmaceuticals (NASDAQ:TELO) has secured $3 million in equity financing through a direct investment from The Bayshore Trust at $3.00 per share, an 18% premium to the market price. This follows a previous $1 million investment at $7.00 per share and complements a $5 million undrawn credit line. The company is advancing two key drug candidates: Telomir-1, a first-in-class age-reversal molecule targeting cellular decline, and Telomir-Ag2, a stabilized Silver(II) compound for drug-resistant infections. Telomir-1 has shown promising preclinical results in multiple indications including Progeria, Type 2 diabetes, Wilson's disease, and oncology. The company plans to submit an IND by year-end, focusing on a rare disease indication to efficiently demonstrate clinical impact.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced Telomir-Ag2 as a novel drug candidate for treating bacterial infections, including drug-resistant pathogens. The breakthrough involves stabilizing Silver(II) in a biologically compatible form using their Telomir-1 platform. In preclinical studies, Telomir-Ag2 showed broad-spectrum antimicrobial activity against various pathogens, including MARSA. The compound targets a significant market opportunity, with the silver wound dressings market projected to reach $1.36 billion by 2030 and the antimicrobial coatings market expected to grow to $33.7 billion by 2031. MARSA alone causes over 323,000 hospitalizations and 10,000 deaths annually in the US. The company plans to advance Telomir-Ag2 into formulation development and IND-enabling studies.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced promising preclinical data for its oral drug candidate, Telomir-1, demonstrating its ability to reverse cellular decline in human cell lines. The drug showed significant improvements in cell viability, mitochondrial function, oxidative stress reduction, calcium signaling, and protection from metal-induced toxicity. Based on these results, Telomir is expanding research into autism spectrum disorder (ASD) and spasmodic dysphonia (SD). The company plans to participate in the FDA's Rare Disease Endpoint Advancement (RDEA) Pilot Program to support development in rare diseases like Progeria and Wilson's disease. The research particularly shows promise for ASD, which affects 1 in 36 children in the US, and SD, which impacts approximately 50,000 Americans.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough preclinical results for its drug Telomir-1 in prostate cancer treatment. The study revealed that Telomir-1 reduced tumor size by approximately 50% in a prostate cancer animal model using aggressive human prostate cancer cells.

Key findings show that Telomir-1 actively suppresses cancer growth and protects against chemotherapy-induced toxicity when combined with Paclitaxel. While Paclitaxel alone showed severe toxicity with one-third mortality in test animals, no deaths occurred when combined with low-dose Telomir-1.

The study also addressed concerns about telomere-elongating drugs potentially promoting cancer, demonstrating instead that Telomir-1 exhibits anti-cancer effects while benefiting healthy cells. The company is advancing Telomir-1 across multiple indications, including age-related macular degeneration and Wilson's disease, with plans to submit an Investigational New Drug application by year-end.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough preclinical findings showing that Telomir-1 successfully reverses calcium dysregulation in multiple human cell lines. The study, using human keratinocyte and retinal cell lines, demonstrated that Telomir-1 restores calcium homeostasis within 10-20 minutes post-exposure and reverses oxidative stress while protecting mitochondrial integrity.

The research revealed that cells treated with Telomir-1 maintained viability despite exposure to extreme oxidative stress, while untreated cells showed degradation. The compound works by blocking calcium influx, preserving mitochondrial function, and preventing cell death pathways activation.

The study positions Telomir-1 as a potential therapeutic for multiple age-related conditions, including Alzheimer's disease, Age-related Macular Degeneration (AMD), Type 2 Diabetes, Wilson's disease, and viral-induced inflammatory conditions. The company is advancing preclinical studies to progress Telomir-1 toward human trials.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced a significant breakthrough in stabilizing both Silver(I) and Silver(II) ions using Telomir-1, making them biologically compatible for medical applications. This achievement addresses a major limitation in silver-based medical treatments.

The breakthrough opens opportunities in the silver wound dressings market, valued at $1.03 billion in 2024 and expected to reach $1.36 billion by 2030. The broader antimicrobial coatings market is projected to grow from $11.65 billion in 2024 to $33.7 billion by 2031, with a 14.2% CAGR.

Silver(II) offers enhanced healing properties compared to Silver(I), including stronger antimicrobial action, accelerated wound healing, and anti-inflammatory properties. The stabilization through Telomir-1 enables applications in burn care, chronic wound management, and medical device coatings.

Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough results from preclinical studies of Telomir-1 in human retinal cell lines, showing significant reduction of copper and iron-induced Reactive Oxygen Species (ROS). The studies demonstrate potential treatment for Age-Related Macular Degeneration (AMD), a leading cause of blindness in adults over 50.

The research revealed that Telomir-1 effectively reduced ROS levels at low concentrations, suggesting regulatory properties rather than chelation effects. This indicates promising therapeutic potential for AMD treatment. The compound targets oxidative stress and metal-induced toxicity, key factors in AMD progression, offering a novel approach compared to current treatments that mainly manage symptoms.

The company plans to conduct AMD disease models to evaluate Telomir-1's efficacy in vivo, while also expanding research into other conditions including Wilson's disease, progeria, cancer, Alzheimer's, and infectious diseases.